Ligand Pharmaceuticals Incorporated (LGND)
-NasdaqGM | Prev Close: | 27.95 |
|---|
| Open: | N/A |
|---|
| Bid: | 27.70 x 100 |
|---|
| Ask: | 2,000.00 x 100 |
|---|
| 1y Target Est: | 34.33 |
|---|
| Beta: | 1.39 |
|---|
| Next Earnings Date: | 9-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 11.96 - 29.92 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 128,051 |
|---|
| Market Cap: | 565.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.01 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Ligand to Present at Upcoming Investor ConferencesBusiness Wire(Thu, May 23)
- LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive AgreementEDGAR Online(Sun, May 19)
- SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals IncorporatedPR Newswire(Fri, May 17)
- LIGAND PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Wed, May 15)
- Ligand Pharmaceuticals Inc. Stock Upgraded (LGND)at TheStreet(Wed, May 15)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 14)
- Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IVBusiness Wire(Tue, May 14)
- Ligand Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Ligand Reports First Quarter Financial ResultsBusiness Wire(Wed, May 8)
- LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Wed, May 8)
- Q1 2013 Ligand Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Wed, May 8)
- Ligand Pharmaceuticals Incorpor Earnings: Your Sneak Peek to the Big Announcementat Wall St. Cheat Sheet(Tue, May 7)
- Big Generic Drug Players See Best Topline Growth Rates in Emerging Markets: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street TranscriptWall Street Transcript(Thu, May 2)
- Ligand Pharmaceuticals acquires portfolio from Selexisat theflyonthewall.com(Tue, Apr 30)
- Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SABusiness Wire(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | 29.73 |
|---|
| P/S (ttm): | 15.12 |
|---|
| Ex-Dividend Date: | 02-Jul-10 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.48 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.07 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | 3.43 |
|---|
Business Summary
Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States.
View More